Back to News
Market Impact: 0.6

FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript

FTLF
Corporate EarningsCompany FundamentalsM&A & Restructuring
FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript

FitLife Brands (NASDAQ:FTLF) reported a Q2 2025 revenue decline of 5% year-over-year to $16.1 million, alongside a 9% drop in gross profit and a gross margin contraction to 42.8%. Net income decreased to $1.7 million from $2.6 million in Q2 2024, primarily attributed to elevated merger and acquisition-related expenses stemming from the recently completed acquisition of Irwin Naturals, which closed subsequent to the reporting period.

Analysis

FitLife Brands reported a weak second quarter for 2025, with total revenue declining 5% year-over-year to $16.1 million. The contraction was also evident in profitability, as gross profit fell 9% and gross margin compressed by 200 basis points to 42.8% from 44.8% in the prior-year period. This pressure on profitability is further highlighted by a 9% decline in contribution to $5.7 million. Net income saw a significant drop to $1.7 million compared to $2.6 million in Q2 2024. However, management attributes most of this decline to elevated merger and acquisition expenses associated with the Irwin Naturals acquisition. Critically, this transaction closed on August 8, 2025, subsequent to the end of the quarter, meaning Q2 results absorbed the deal-related costs without yet reflecting any potential revenue or synergistic benefits from the newly acquired entity.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly negative

Sentiment Score

-0.65

Ticker Sentiment

FTLF-0.75

Key Decisions for Investors

  • Investors should look past the headline net income figure and normalize Q2 earnings for the one-time M&A expenses to better assess the core operational health of the business.
  • The primary focus should now be on the successful integration of Irwin Naturals and management's ability to realize anticipated revenue and cost synergies in the upcoming quarters.
  • Monitor for any stabilization or improvement in the legacy business's top-line and gross margins, as the reported 5% revenue decline and margin compression raise questions about underlying demand and competitive pressures independent of the acquisition.